» Articles » PMID: 31465556

A Bile Duct-on-a-Chip With Organ-Level Functions

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2019 Aug 30
PMID 31465556
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Chronic cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are frequently associated with damage to the barrier function of the biliary epithelium. Here, we report on a bile duct-on-a-chip that phenocopies not only the tubular architecture of the bile duct in three dimensions, but also its barrier functions.

Approach And Results: We showed that mouse cholangiocytes in the channel of the device became polarized and formed mature tight junctions, that the permeability of the cholangiocyte monolayer was comparable to ex vivo measurements, and that cholangiocytes in the device were mechanosensitive (as demonstrated by changes in calcium flux under applied luminal flow). Permeability decreased significantly when cells formed a compact monolayer with cell densities comparable to those observed in vivo. This device enabled independent access to the apical and basolateral surfaces of the cholangiocyte channel, allowing proof-of-concept toxicity studies with the biliary toxin, biliatresone, and the bile acid, glycochenodeoxycholic acid. The cholangiocyte basolateral side was more vulnerable than the apical side to treatment with either agent, suggesting a protective adaptation of the apical surface that is normally exposed to bile. Further studies revealed a protective role of the cholangiocyte apical glycocalyx, wherein disruption of the glycocalyx with neuraminidase increased the permeability of the cholangiocyte monolayer after treatment with glycochenodeoxycholic acid.

Conclusions: This bile duct-on-a-chip captured essential features of a simplified bile duct in structure and organ-level functions and represents an in vitro platform to study the pathophysiology of the bile duct using cholangiocytes from a variety of sources.

Citing Articles

The utilisation of biliary organoids for biomedical applications.

Lei Z, Yang Y, Xiang Y Front Bioeng Biotechnol. 2025; 12():1501829.

PMID: 39845376 PMC: 11753252. DOI: 10.3389/fbioe.2024.1501829.


Biliary atresia susceptibility gene EFEMP1 regulates extrahepatic bile duct elastic fiber formation and mechanics.

Gupta K, Llewellyn J, Roberts E, Liu C, Naji A, Assoian R JHEP Rep. 2024; 7(1):101215.

PMID: 39717503 PMC: 11663959. DOI: 10.1016/j.jhepr.2024.101215.


Recent research progresses of bioengineered biliary stents.

Yan J, Ye Z, Wang X, Zhong D, Wang Z, Yan T Mater Today Bio. 2024; 29:101290.

PMID: 39444940 PMC: 11497374. DOI: 10.1016/j.mtbio.2024.101290.


Liver-on-chips for drug discovery and development.

Mehta V, Karnam G, Madgula V Mater Today Bio. 2024; 27:101143.

PMID: 39070097 PMC: 11279310. DOI: 10.1016/j.mtbio.2024.101143.


Biliary atresia.

Tam P, Wells R, Tang C, Lui V, Hukkinen M, Luque C Nat Rev Dis Primers. 2024; 10(1):47.

PMID: 38992031 DOI: 10.1038/s41572-024-00533-x.


References
1.
Griep L, Wolbers F, de Wagenaar B, ter Braak P, Weksler B, Romero I . BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed Microdevices. 2012; 15(1):145-50. DOI: 10.1007/s10544-012-9699-7. View

2.
Adamson R, Lenz J, Curry F . Quantitative laser scanning confocal microscopy on single capillaries: permeability measurement. Microcirculation. 1994; 1(4):251-65. DOI: 10.3109/10739689409146752. View

3.
Nakanuma Y, Tsuneyama K, Gershwin M, Yasoshima M . Pathology and immunopathology of primary biliary cirrhosis with emphasis on bile duct lesions: recent progress. Semin Liver Dis. 1995; 15(4):313-28. DOI: 10.1055/s-2007-1007284. View

4.
Booth R, Kim H . Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). Lab Chip. 2012; 12(10):1784-92. DOI: 10.1039/c2lc40094d. View

5.
Sampaziotis F, de Brito M, Madrigal P, Bertero A, Saeb-Parsy K, Soares F . Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat Biotechnol. 2015; 33(8):845-852. PMC: 4768345. DOI: 10.1038/nbt.3275. View